Enjin Co., Ltd. Logo

Enjin Co., Ltd.

PR firm for SMEs and medical institutions, offering consulting and a media matching platform.

7370 | T

Overview

Corporate Details

ISIN(s):
JP3168750002
LEI:
Country:
Japan
Address:
中央区銀座5−13−16
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Enjin Co., Ltd. is a public relations firm specializing in branding and strategic communications. The company provides comprehensive PR consulting services, including research, analysis, and long-term strategy development, primarily for small and medium-sized enterprises, corporations, and medical institutions. A key offering is "Medichoku," a proprietary media matching platform that connects clients directly with media outlets to secure exposure and enhance brand recognition. Additionally, Enjin operates a corporate venture capital arm to invest in and support startups, aiming to foster innovation and new market creation.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-21 08:16
Registration Form
確認書
Japanese 8.7 KB
2025-08-21 08:15
Registration Form
有価証券報告書-第19期(2024/06/01-2025/05/31)
Japanese 1.0 MB
2025-06-17 07:27
Governance Information
訂正内部統制報告書-第16期(2021/06/01-2022/05/31)
Japanese 26.0 KB
2025-06-17 07:24
Governance Information
訂正内部統制報告書-第17期(2022/06/01-2023/05/31)
Japanese 26.6 KB
2025-06-17 07:19
Governance Information
訂正内部統制報告書-第18期(2023/06/01-2024/05/31)
Japanese 26.7 KB
2025-01-14 09:00
Report Publication Announcement
確認書
Japanese 8.8 KB
2025-01-14 08:54
Interim Report
半期報告書-第19期(2024/06/01-2025/05/31)
Japanese 219.6 KB
2024-08-26 08:02
Post-Annual General Meeting Information
臨時報告書
Japanese 28.9 KB
2024-08-26 07:51
Governance Information
内部統制報告書-第18期(2023/06/01-2024/05/31)
Japanese 23.3 KB
2024-08-26 07:44
Registration Form
確認書
Japanese 8.7 KB
2024-08-26 07:35
Registration Form
有価証券報告書-第18期(2023/06/01-2024/05/31)
Japanese 1008.8 KB
2024-04-12 08:17
Report Publication Announcement
確認書
Japanese 8.8 KB
2024-04-12 08:13
Quarterly Report
四半期報告書-第18期第3四半期(2023/12/01-2024/02/29)
Japanese 167.8 KB
2024-01-12 07:42
Quarterly Report
確認書
Japanese 8.8 KB
2024-01-12 07:33
Quarterly Report
四半期報告書-第18期第2四半期(2023/09/01-2023/11/30)
Japanese 205.2 KB

Automate Your Workflow. Get a real-time feed of all Enjin Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Enjin Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Enjin Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Noile-Immune Biotech Inc. Logo
Developing PRIME technology-enhanced CAR-T cell immunotherapies for treating solid tumors.
Japan
4893
NRGene Technologies Ltd. Logo
AI-powered genomic analysis software to accelerate and optimize plant and animal breeding.
Israel
NRGN
Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150

Talk to a Data Expert

Have a question? We'll get back to you promptly.